# Pizarra — PT-pseudo_3cc88c81f35a (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_3cc88c81f35a
Task: 1

Encounter: Urology - outpatient on 27 Jan 2025.
Referrer: Dr. M. Jansen (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 66-year-old male
  - PSA: 8.3 ng/mL
  - mpMRI — PI-RADS score: 2 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.206 ng/mL²
  - PSA velocity: 0.78 ng/mL/yr
  - Prior PSA: 6.7 ng/mL
  - Prostate volume: 40.2 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.69907415 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 8.3 ng/mL. PI-RADS 2. PSAD 0.21. Prostate volume 40 mL. DRE nodus. csPCa 0.70.

Vitals: weight 85 kg, height 180 cm, BMI 26.2, BP 114/76 mmHg, HR 88 bpm. Smoking: Ex-smoker (11 pack-yr, quit 2010).

Chief complaint: Clinical review sought after a previous prostate biopsy and a recent PSA increase to 8.3 ng/mL.

History: He is a 66-year-old man initially flagged for an elevated PSA during routine primary care screening in 2023. Subsequent monitoring involved serial blood work and a previous biopsy that returned Positive for low-grade disease. He works as a retired warehouse worker, remains married, and shares a multi-generational household with his spouse and an adult child. Daily life revolves around gardening rather than formal exercise. He is an Ex-smoker (11 pack-yr, quit 2010), while alcohol intake remains minimal at roughly one unit weekly. He experiences occasional mild urinary hesitancy and nocturia, corresponding to an IPSS score of 17, yet explicitly denies bone pain, unexplained weight loss, or haematuria. Comorbidities: none. Active medication: None.

Physical examination: DRE: firm, asymmetrically enlarged prostate with a discrete Nodus palpable in the left peripheral zone. The rest of the abdominal and cardiovascular evaluation remains unremarkable, documenting a blood pressure of 114/76 mmHg and a steady heart rate of 88 bpm. Overall, he presents as well-appearing without pallor or peripheral lymphadenopathy.

Patient info: retired warehouse worker; Married; Lives with adult child (multi-generational household).
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 1 units / week; exercise Gardening, no structured exercise; IPSS score: 17/35 (moderate LUTS).


Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.40 +/- 0.13   (95% CI 0.15-0.64)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.13  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.97 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'discuss': p +/- dp straddles 0.5. The classifier genuinely CANNOT tell the two answers apart here. Its number is a starting point only. Measured accuracy in this tier on the labelled cohort: 0.488 over 43 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size/zone compare against an earlier study?
  - psa_trend (get_psa_trend) -> What is the serial PSA trajectory beyond the headline value?
  - previous_notes (get_previous_notes) -> What was the prior grade, surveillance pathway, and management agreement?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with current imaging and PSA trend, warrants a biopsy decision, as the visible panel is insufficient. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the clinical context that the prior biopsy was positive, which fundamentally changes the question from "does he have cancer?" to "is the disease progressing or is this a recurrence/new lesion?" Specifically, it did not weigh the specific PI-RADS 2 score against the rising PSA velocity (0.78 ng/mL/yr) or the prior positive biopsy status. It also failed to weigh the clinical significance of the prior positive diagnosis against the current low PI-RADS score.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a probability of 0.40 +/- 0.13. This suggestion could be wrong because the classifier's high aleatoric uncertainty (H=0.97) indicates the model cannot distinguish between the two outcomes based on the input features. Furthermore, the guideline search suggests that the decision hinges on retrieved documents (MRI, PSA trend, prior notes), which the prior ignored, meaning its suggestion is based on insufficient data for this specific clinical scenario.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
1. radiology_report (get_mri_report) -> To determine if the current mpMRI lesion size/zone compares against an earlier study, which is critical for assessing progression.
2. psa_trend (get_psa_trend) -> To establish the serial PSA trajectory beyond the headline value, which is necessary to assess the rate of change.
3. previous_notes (get_previous_notes) -> To ascertain the prior grade, surveillance pathway, and management agreement, which is central to the guideline criterion.
4. laboratory_results (get_laboratory_results) -> Although the moderator dropped this, retrieving the full panel might provide context on other markers that could influence the decision.

GUIDELINE ANCHOR
The guideline search indicates that the decision must be determined by retrieved documents: "The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed."

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_3cc88c81f35a", "radiology_report": "Subject: Multiparametric MRI of the Prostate | Ziekenhuis Gelderse Vallei, Ede | 24 January 2025\n\nClinical indication: Re-evaluation for rising PSA (8.3 ng/mL) and prior positive biopsy.\n\nFINDINGS: The gland measures 40.2 mL in total volume, appearing homogeneous on T2-weighted imaging with mild transition zone enlargement. A roughly 6 mm well-defined nodule with benign characteristics occupies the anterior transition zone apex. The peripheral zone lacks any focal T2-hypointense lesions. Symmetric diffusion is observed on DWI, showing no restricted uptake, while dynamic contrast enhancement remains negative for early focal signals. There is no evidence of extraprostatic extension, seminal vesicle invasion, or suspicious pelvic lymphadenopathy.\n\nIMPRESSION: PI-RADS 2. Prostate volume 40.2, PSA density 0.206. No PI-RADS 3+ lesion identified. csPCa predicted probability 0.69907415."}
get_psa_trend
{"case_id": "PT-pseudo_3cc88c81f35a", "psa_trend": [{"date": "May 2023", "val": 2.5}, {"date": "Dec 2023", "val": 4.2}, {"date": "Jul 2024", "val": 7.2}, {"date": "Jan 2025", "val": 8.3}]}
get_previous_notes
{"case_id": "PT-pseudo_3cc88c81f35a", "previous_notes": [{"date": "01 Jun 2024", "author": "Dr. M. Jansen (GP)", "text": "Serial screening detected a PSA value of 6.7 ng/mL, marking a modest rise from the preceding 6.4 ng/mL measurement. Aside from occasional mild urinary frequency, he experiences no lower urinary tract symptoms. A follow-up blood draw was planned for late summer to track the trend prior to any specialist involvement."}, {"date": "29 Sep 2024", "author": "Dr. M. Jansen (GP)", "text": "Clinical review focused on the persistent PSA elevation. Latest labs indicate a further climb to 8.3 ng/mL alongside a %free PSA reading of 18%. Consequently, a urology outpatient appointment was booked for comprehensive assessment, and prior scan and biopsy records were requested for the visit."}]}
NOT RETRIEVED
laboratory_results
Left closed because the moderator explicitly dropped this document from the agenda, and no information from the retrieved documents raised a specific question requiring it.
WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- PSA velocity: 0.78 ng/mL/yr (indicating a significant rate of rise).
- Previous notes: Prior biopsy was positive for low-grade disease, suggesting the need for re-evaluation.
AGAINST sampling this patient now:
- mpMRI report: PI-RADS score of 2, with no PI-RADS 3+ lesion identified.
- mpMRI report: Lesion characteristics are benign (6 mm well-defined nodule with benign characteristics).
WHERE THIS LEANS
The rising PSA velocity and prior positive biopsy suggest a need for further investigation, but the current low PI-RADS score and benign MRI findings temper the urgency for immediate biopsy.
LEAN: unclear

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=no, protocol=abstains, evidence=abstains.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved documents provide conflicting signals: rising PSA velocity and prior positive biopsy suggest investigation, but the current PI-RADS 2 and benign MRI findings temper urgency. The record is insufficient as the guideline criterion remains unresolved by the evidence.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: NO BIOPSY   (confidence: clear)

Deferring is the correct decision because the guideline criterion abstained, and the retrieved documents did not provide a specific reason to proceed with a re-biopsy. The rising PSA velocity (0.78 ng/mL/yr) and prior positive biopsy suggest investigation, but the current PI-RADS 2 score and benign MRI findings temper the urgency. The statistical prior suggested no biopsy, and the retrieved evidence did not overturn this suggestion.

Variables that carried weight: bx=important, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
